Latest

Learn how lung cancer MRD ctDNA testing detects molecular residual disease, what positive and negative results mean, how it can precede recurrence on scans, and why treatment decisions still require clinical context.

Minimal Residual Disease ctDNA Test for Lung Cancer: Recurrence Monitoring, MRD, and Tumor DNA

Learn what MSI testing means in lung cancer, how MSI-H, MSS, dMMR, and pMMR results differ, how NGS, PCR, and IHC are used, and why this rare biomarker can matter for immunotherapy and hereditary evaluation.

MSI Test for Lung Cancer: Microsatellite Instability, Mismatch Repair, and Result Meaning

Learn how Napsin A IHC supports lung adenocarcinoma diagnosis, what positive granular cytoplasmic staining means, why negative results do not exclude lung cancer, and when other tumor origins must be considered.

Napsin A IHC Test for Lung Cancer: Adenocarcinoma Marker, Tumor Origin, and Positive...

Non-Small Cell Lung Cancer Biomarker Test: Driver Mutations, PD-L1, and Molecular Profile

Learn what an NSE blood test means in small cell lung cancer, why levels can be high, how hemolysis causes false elevations, and how serial NSE trends may support treatment and recurrence monitoring.

NSE Test for Lung Cancer: Small Cell Lung Cancer Marker, High Levels, and...

Understand NTRK fusion testing in lung cancer, including tumor-agnostic meaning, RNA NGS, pan-TRK IHC, positive results, negative-result limits, and next steps.

NTRK Fusion Test for Lung Cancer: Gene Fusion, Tumor-Agnostic Marker, and Molecular Meaning

Diagnostics

Home Diagnostics

Learn how p40 IHC helps classify lung squamous cell carcinoma, what positive nuclear staining means, how p40 compares with p63 and TTF-1, and its key limitations.

p40 IHC Test for Lung Cancer: Squamous Cell Marker, Tumor Classification,...

Understand the PD-L1 test for lung cancer, including TPS score ranges, protein-expression meaning, assay differences, result limits, and how PD-L1 guides NSCLC treatment.

PD-L1 Test for Lung Cancer: TPS Score, Protein Expression, and Result...

Understand the ProGRP test for lung cancer, including SCLC marker ranges, kidney effects, tumor-burden trends, treatment monitoring, NSE comparison, and result meaning.

ProGRP Test for Lung Cancer: Small Cell Lung Cancer Marker, Tumor...

Understand RET fusion testing in lung cancer, including positive-result meaning, KIF5B and CCDC6 partners, RNA NGS versus FISH, negative-result limits, and next steps.

RET Fusion Test for Lung Cancer: Gene Fusion, Positive Result, and...

Understand ROS1 fusion testing in lung cancer, including what a positive result means, RNA NGS versus FISH, negative-result limits, and molecular significance.

ROS1 Fusion Test for Lung Cancer: Gene Fusion, Positive Result, and...

Understand the SCC antigen test for lung cancer, including normal-range limits, causes of high results, squamous cell carcinoma relevance, and monitoring use.

SCC Antigen Test for Lung Cancer: Squamous Cell Carcinoma Marker and...

Understand how ProGRP, NSE, and DLL3 biomarkers are used in small cell lung cancer, including blood-test trends, DLL3 expression, monitoring limits, and result interpretation.

Small Cell Lung Cancer Biomarker Panel: ProGRP, NSE, DLL3, and Disease...

Learn how the TTF-1 IHC test helps identify lung adenocarcinoma, what positive or negative nuclear staining means, and why other markers are needed.

TTF-1 IHC Test for Lung Cancer: Tumor Origin, Adenocarcinoma Marker, and...

Learn what a lung cancer TMB test measures, how mutations per megabase are calculated, what TMB-high means, and how the score fits with PD-L1, NGS, and immunotherapy decisions.

Tumor Mutational Burden (TMB) Test for Lung Cancer: Mutation Load, Genomic...

Learn how blood-based multi-cancer early detection tests find cancer signals, what positive and negative results mean, and what follow-up may involve.

Blood-Based Multi-Cancer Early Detection Test: Cancer Signals, Screening, and Follow-Up

CancerSEEK combines tumor DNA mutations and protein markers for multi-cancer detection. Learn what research shows, how results are interpreted, and why follow-up matters.

CancerSEEK Test: Multi-Cancer Blood Test, Tumor Markers, and Early Detection Research

Understand how cell-free DNA cancer tests detect tumor DNA, mutations, and blood-based genomic signals, plus what positive, negative, and inconclusive results mean.

Cell-Free DNA Cancer Test: Tumor DNA in Blood, Mutation Detection, and...

Learn how circulating tumor cell tests detect tumor cells in blood, what CTC counts can mean for prognosis, and how CTC testing compares with ctDNA liquid biopsy.

Circulating Tumor Cell (CTC) Test: Tumor Cells in Blood, Cancer Monitoring,...

Learn what high circulating tumor cell counts mean, including common CTC thresholds, prognosis, tumor-burden limits, treatment trends, and result interpretation.

Circulating Tumor Cell Count Test: High Levels, Tumor Cell Burden, and...

Learn how a ctDNA test detects tumor DNA in blood, what mutations and MRD results mean, how ctDNA tracks treatment, and how it relates to recurrence risk.

Circulating Tumor DNA (ctDNA) Test: Cancer Monitoring, Mutations, MRD, and Recurrence...

Learn what a ctDNA MRD test means, how tumor-informed and tumor-naive testing differ, and how positive or negative results relate to cancer recurrence risk.

ctDNA Minimal Residual Disease (MRD) Test: Recurrence Risk, Tumor DNA Monitoring,...

Learn how a ctDNA mutation panel finds tumor mutations and resistance markers in blood, what actionable and negative results mean, and when tissue testing is still needed.

ctDNA Mutation Panel: Tumor Mutations, Blood-Based Genomic Testing, and Resistance Markers

$Learn what a ctDNA tumor fraction test measures, how blood DNA percentage is calculated, what low or high results may mean, and why assay limits matter.$

ctDNA Tumor Fraction Test: Cancer Burden, Blood DNA Percentage, and Result...

EGFR T790M Liquid Biopsy Test: Lung Cancer Resistance Mutation and ctDNA...

Learn what an ESR1 liquid biopsy detects, how positive and negative ctDNA results are interpreted, and how emerging ESR1 mutations can guide advanced breast cancer therapy.

ESR1 Liquid Biopsy Test: Breast Cancer Hormone Resistance Marker and ctDNA...

12 3...92 Page 1 of 92